COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations
Authors:
Open Access
- 14 December 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (46) , 7969-7981
Abstract
The coronavirus disease 2019 (COVID-19) has caused one of the worst public health crises in modern history. Even though severe acute respiratory syndrome coronavirus 2 primarily affects the respiratory tract, gastrointestinal manifestations are well described in literature. This review will discuss the epidemiology, virology, manifestations, immunosuppressant states, and lessons learned from COVID-19. Observations: At the time of writing, COVID-19 had infected more than 111 million people and caused over 2.5 million deaths worldwide. Multiple medical comorbidities including obesity, pre-existing liver condition and the use of proton pump inhibitor have been described as risk factor for severe COVID-19. COVID-19 most frequently causes diarrhea (12.4%), nausea/vomiting (9%) and elevation in liver enzymes (15%-20%). The current data does not suggest that patients on immunomodulators have a significantly increased risk of mortality from COVID-19. The current guidelines from American Gastroenterological Association and American Association for the Study of Liver Diseases do not recommend pre-emptive changes in patients on immunosuppression if the patients have not been infected with COVID-19. Conclusions and relevance: The COVID-19 pandemic has prompted a change in structure and shape of gastroenterology departmental activities. Endoscopy should be performed only when necessary and with strict protective measures. Online consultations in the form of telehealth services and home drug deliveries have revolutionized the field.Keywords
This publication has 74 references indexed in Scilit:
- Creg in Hepatocytes Ameliorates Liver Ischemia/Reperfusion Injury in a TAK1‐Dependent Manner in MiceHepatology, 2019
- Complexity of the Basic Reproduction Number (R0)Emerging Infectious Diseases, 2019
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- Adverse Events of Proton Pump Inhibitors: Potential MechanismsCurrent Drug Metabolism, 2018
- ACG Clinical Guideline: Management of Crohn's Disease in AdultsAmerican Journal of Gastroenterology, 2018
- An ALOX12–12-HETE–GPR31 signaling axis is a key mediator of hepatic ischemia–reperfusion injuryNature Medicine, 2017
- Crohn's diseaseThe Lancet, 2017
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Increased Risk of Pneumonia Among Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2013
- A succinct review of the general and immunological pharmacologic effects of proton pump inhibitorsJournal of Clinical Pharmacy and Therapeutics, 2008